Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

2.

Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy.

van Elsas A, Sutmuller RP, Hurwitz AA, Ziskin J, Villasenor J, Medema JP, Overwijk WW, Restifo NP, Melief CJ, Offringa R, Allison JP.

J Exp Med. 2001 Aug 20;194(4):481-9.

3.

CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy.

Chambers CA, Kuhns MS, Egen JG, Allison JP.

Annu Rev Immunol. 2001;19:565-94. Review.

PMID:
11244047
4.

Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates the size, reactivity, and function of a primed pool of CD4+ T cells.

Kuhns MS, Epshteyn V, Sobel RA, Allison JP.

Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12711-6.

5.
6.

CTLA-4 gene polymorphism may modulate disease in Japanese multiple sclerosis patients.

Fukazawa T, Yanagawa T, Kikuchi S, Yabe I, Sasaki H, Hamada T, Miyasaka K, Gomi K, Tashiro K.

J Neurol Sci. 1999 Dec 1;171(1):49-55.

PMID:
10567049
8.

Defective CTLA-4 cycling pathway in Chediak-Higashi syndrome: a possible mechanism for deregulation of T lymphocyte activation.

Barrat FJ, Le Deist F, Benkerrou M, Bousso P, Feldmann J, Fischer A, de Saint Basile G.

Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8645-50.

9.

The CTLA-4 gene is associated with multiple sclerosis.

Ligers A, Xu C, Saarinen S, Hillert J, Olerup O.

J Neuroimmunol. 1999 Jun 1;97(1-2):182-90.

PMID:
10408973
10.

Autoantibodies to T cell costimulatory molecules in systemic autoimmune diseases.

Matsui T, Kurokawa M, Kobata T, Oki S, Azuma M, Tohma S, Inoue T, Yamamoto K, Nishioka K, Kato T.

J Immunol. 1999 Apr 1;162(7):4328-35.

11.

CTLA4 promoter and exon 1 dimorphisms in multiple sclerosis.

Harbo HF, Celius EG, Vartdal F, Spurkland A.

Tissue Antigens. 1999 Jan;53(1):106-10.

PMID:
10082437
13.

New genetic loci that control susceptibility and symptoms of experimental allergic encephalomyelitis in inbred mice.

Butterfield RJ, Sudweeks JD, Blankenhorn EP, Korngold R, Marini JC, Todd JA, Roper RJ, Teuscher C.

J Immunol. 1998 Aug 15;161(4):1860-7.

14.
15.

Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand.

Balashov KE, Smith DR, Khoury SJ, Hafler DA, Weiner HL.

Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):599-603.

16.

IL-12 unmasks latent autoimmune disease in resistant mice.

Segal BM, Shevach EM.

J Exp Med. 1996 Aug 1;184(2):771-5.

17.

CTLA-4: a negative regulator of autoimmune disease.

Karandikar NJ, Vanderlugt CL, Walunas TL, Miller SD, Bluestone JA.

J Exp Med. 1996 Aug 1;184(2):783-8.

18.

CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis.

Perrin PJ, Maldonado JH, Davis TA, June CH, Racke MK.

J Immunol. 1996 Aug 15;157(4):1333-6.

PMID:
8759711
19.

Genetic analysis of susceptibility to experimental autoimmune encephalomyelitis in a cross between SJL/J and B10.S mice.

Encinas JA, Lees MB, Sobel RA, Symonowicz C, Greer JM, Shovlin CL, Weiner HL, Seidman CE, Seidman JG, Kuchroo VK.

J Immunol. 1996 Sep 1;157(5):2186-92.

PMID:
8757345
20.

Immunogenic and encephalitogenic epitope clusters of myelin proteolipid protein.

Greer JM, Sobel RA, Sette A, Southwood S, Lees MB, Kuchroo VK.

J Immunol. 1996 Jan 1;156(1):371-9.

PMID:
8598487
Items per page

Supplemental Content

Write to the Help Desk